A protective AAV vaccine for SARS-CoV-2.

Zhao, Simeng; Ke, Junzi; Yang, Boyu; Tan, Fangzhi; Yang, Jie; Lin, Chao-Po; Wang, Haopeng; Zhong, Guisheng

Zhao, Simeng; Ke, Junzi; Yang, Boyu; Tan, Fangzhi; Yang, Jie; Lin, Chao-Po; Wang, Haopeng; Zhong, Guisheng.

Afiliação

Zhao S; iHuman Institute, ShanghaiTech University, 201210, Shanghai, China.
Ke J; iHuman Institute, ShanghaiTech University, 201210, Shanghai, China.
Yang B; School of Life Science and Technology, ShanghaiTech University, 201210, Shanghai, China.
Tan F; iHuman Institute, ShanghaiTech University, 201210, Shanghai, China.
Yang J; School of Life Science and Technology, ShanghaiTech University, 201210, Shanghai, China.
Lin CP; iHuman Institute, ShanghaiTech University, 201210, Shanghai, China.
Wang H; iHuman Institute, ShanghaiTech University, 201210, Shanghai, China.
Zhong G; School of Life Science and Technology, ShanghaiTech University, 201210, Shanghai, China.

Signal Transduct Target Ther ; 7(1): 310, 2022 09 05.

Article em En | MEDLINE | ID: mdl-36064820

Assuntos

COVID-19; Vacinas Virais; COVID-19/prevenção & controle; Vacinas contra COVID-19/uso terapêutico; Humanos; SARS-CoV-2; Glicoproteína da Espícula de Coronavírus; Vacinas Virais/uso terapêutico

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / COVID-19 Limite: Humans Idioma: En Revista: Signal Transduct Target Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google